2022
ALDH1A1 overexpression in melanoma cells promotes tumor angiogenesis by activating the IL-8/Notch signaling cascade
Ciccone V, Terzuoli E, Ristori E, Filippelli A, Ziche M, Morbidelli L, Donnini S. ALDH1A1 overexpression in melanoma cells promotes tumor angiogenesis by activating the IL-8/Notch signaling cascade. International Journal Of Molecular Medicine 2022, 50: 99. PMID: 35656893, PMCID: PMC9186295, DOI: 10.3892/ijmm.2022.5155.Peer-Reviewed Original ResearchConceptsIL-8Endothelial cellsMelanoma cellsTumor cellsALDH1A1 expressionAngiogenic factorsAngiogenic featuresTumor microenvironmentCancer cellsPoor clinical outcomeHigher microvessel densityNumber of cancersPro-angiogenic phenotypeOverexpression of ALDH1A1ALDH1A1 overexpressionClinical outcomesCo-culture systemMicrovessel densityImmunodeficient miceNF-kBProangiogenic factorsMelanoma cancer cellsTumor angiogenesisMelanoma controlStromal cells
2020
Cutaneous Toxicities of Immune Checkpoint Inhibitors: The Role of the Dermatologist.
Tattersall IW, Leventhal JS. Cutaneous Toxicities of Immune Checkpoint Inhibitors: The Role of the Dermatologist. The Yale Journal Of Biology And Medicine 2020, 93: 123-132. PMID: 32226342, PMCID: PMC7087048.Peer-Reviewed Original ResearchConceptsCutaneous irAEsImmune checkpoint inhibitor therapyCheckpoint inhibitor therapyImmune checkpoint inhibitionImmune checkpoint inhibitorsPotential adverse eventsPotential prognostic significanceNumber of cancersOnly carcinogenesisCheckpoint inhibitorsAdverse eventsCutaneous toxicityInhibitor therapyCheckpoint inhibitionPrognostic significanceCommon siteClinical characterizationPrimary dermatosesIrAEsTherapeutic promiseTreatment of diseasesTherapyCancerTreatmentDermatologists
2019
Phase I study of pembrolizumab in people with HIV and cancer.
Uldrick T, Goncalves P, Abdul Hay M, Claeys A, Emu B, Ernstoff M, Fong L, Kaiser J, Kohrt H, Lacroix A, Lee S, Lundgren L, Lurain K, Parsons C, Peeramsetti S, Ramaswami R, Sharon E, Wang C, Yarchoan R, Cheever M. Phase I study of pembrolizumab in people with HIV and cancer. Journal Of Clinical Oncology 2019, 37: 2500-2500. DOI: 10.1200/jco.2019.37.15_suppl.2500.Peer-Reviewed Original ResearchAdverse eventsNon-Hodgkin lymphomaAntiretroviral therapyViral loadClinical benefitAnti-PD-1/PD-L1 therapyCD4 cells/μL.Elevated AST/ALTMedian age 57 yearsMulticenter phase 1 trialTreatment-emergent adverse eventsEmergent adverse eventsHBV/HCVSquamous cell skinPD-L1 therapyAge 57 yearsHIV viral loadAST/ALTPhase 1 trialCells/Cells/μL.Multicentric Castleman's diseaseAppropriate eligibility criteriaImmuno-oncology studiesNumber of cancers
2017
The receptor tyrosine kinase AXL promotes migration and invasion in colorectal cancer
Uribe DJ, Mandell EK, Watson A, Martinez JD, Leighton JA, Ghosh S, Rothlin CV. The receptor tyrosine kinase AXL promotes migration and invasion in colorectal cancer. PLOS ONE 2017, 12: e0179979. PMID: 28727830, PMCID: PMC5519024, DOI: 10.1371/journal.pone.0179979.Peer-Reviewed Original ResearchConceptsColorectal cancerTAM receptor tyrosine kinasesReceptor tyrosine kinasesLate-stage colorectal cancerColitis-associated cancerStage colorectal cancerAnti-inflammatory effectsReceptor tyrosine kinase AXLTyro3 receptor tyrosine kinasesSufficient therapeutic benefitTyrosine kinase AXLNumber of cancersTYRO3 expressionChronic inflammationAllergic responsesTherapeutic benefitTumor cell migrationImmunological diseasesExpression associatesIndiscriminate inhibitionGene signatureAxlAxl kinase activityInflammationCancer
2014
Automated Quantitative Analysis of Tissue Microarray of 443 Patients with Colorectal Adenocarcinoma: Low Expression of Bcl-2 Predicts Poor Survival
Nicholson AD, Guo X, Sullivan CA, H. CH. Automated Quantitative Analysis of Tissue Microarray of 443 Patients with Colorectal Adenocarcinoma: Low Expression of Bcl-2 Predicts Poor Survival. Journal Of The American College Of Surgeons 2014, 219: 977-987. PMID: 25127509, DOI: 10.1016/j.jamcollsurg.2014.07.007.Peer-Reviewed Original ResearchConceptsDisease-specific survivalBcl-2 expressionColorectal cancerOverall survivalPoor disease-specific survivalCox proportional hazards modelIndependent prognostic factorSubset of patientsColorectal adenocarcinoma samplesLog-rank testBcl-2Proportional hazards modelSemi-quantitative grading methodsColorectal cancer samplesNumber of cancersPrognostic factorsT stageChemotherapy choiceClinicopathologic variablesColorectal adenocarcinomaUnivariate analysisPatient outcomesPoor survivalTissue microarrayAggressive phenotype
2012
Evaluation of Molecular Breast Imaging in Women Undergoing Myocardial Perfusion Imaging with Tc-99m Sestamibi
Hruska CB, Rhodes DJ, Collins DA, Tortorelli CL, Askew JW, O'Connor MK. Evaluation of Molecular Breast Imaging in Women Undergoing Myocardial Perfusion Imaging with Tc-99m Sestamibi. Journal Of Women's Health 2012, 21: 730-738. PMID: 22404787, DOI: 10.1089/jwh.2011.3267.Peer-Reviewed Original ResearchConceptsMolecular breast imagingBreast diseaseBreast cancerDiagnostic yieldMyocardial perfusionHigh-risk benign breast lesionsMyocardial perfusion stress testingRecent negative mammogramStress myocardial perfusionHigh diagnostic yieldStress myocardial perfusion studyBenign breast lesionsNumber of cancersMyocardial perfusion studiesBreast imagingNew cancersRecent mammogramSestamibi injectionNegative mammogramUnnecessary workupPerfusion studiesBreast lesionsCancerIsotope injectionWomen
2003
Microarrays and clinical dentistry
Kuo W, Whipple M, Jenssen T, Todd R, Epstein J, Ohno-Machado L, Sonis S, Park P. Microarrays and clinical dentistry. The Journal Of The American Dental Association 2003, 134: 456-462. PMID: 12733779, DOI: 10.14219/jada.archive.2003.0195.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAdvanced microarray technologiesEntire human genomeActivity of genesGene expression patternsHuman Genome ProjectGenome levelHuman genomeGenetic approachesCellular developmentDNA sequencesGenome ProjectExciting biologyCandidate genesExpression patternsMicroarray technologyMicroarrayNumber of cancersGenesMolecular profileAnalysis of diseasesMolecular behaviorGenomeBiologyTissue samplesProteinPriorities for development of research methods in occupational cancer.
Ward EM, Schulte PA, Bayard S, Blair A, Brandt-Rauf P, Butler MA, Dankovic D, Hubbs AF, Jones C, Karstadt M, Kedderis GL, Melnick R, Redlich CA, Rothman N, Savage RE, Sprinker M, Toraason M, Weston A, Olshan AF, Stewart P, Zahm SH, Team O. Priorities for development of research methods in occupational cancer. Environmental Health Perspectives 2003, 111: 1-12. PMID: 12524210, PMCID: PMC1241299, DOI: 10.1289/ehp.111-1241299.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNational Occupational Research AgendaOccupational cancerOccupational cancer researchNumber of cancersCancer researchSecondary preventionSignificant morbidityOccupational cohortOccupational carcinogensEpidemiologic studiesOccupational factorsCarcinogenic processHealth effectsCancerEnvironmental toxicantsIndustrial HygienistsPriority research areasMorbidityRisk assessmentCohortMortalityTeam of expertsHygienistsPrevention
1993
Hyperechoic renal cell carcinomas: increase in detection at US.
Forman H, Middleton W, Melson G, McClennan B. Hyperechoic renal cell carcinomas: increase in detection at US. Radiology 1993, 188: 431-4. PMID: 8327692, DOI: 10.1148/radiology.188.2.8327692.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaSmall cancersSmall renal cell carcinomaNormal renal parenchymaNumber of cancersTumor sizeCell carcinomaLarge tumorsRenal parenchymaTumor echogenicityFrequency of detectionSonographic featuresSmall tumorsIncreased detectionAngiomyolipomaTumorsCancerRecent reportsPatientsCarcinomaEchogenicityParenchyma
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply